Topical calcineurin inhibitors in eczema and cancer association: A cohort study

Abstract

Introduction: Cancer risk associated with topical calcineurin inhibitors (TCIs) remains unclear. Objective: To evaluate the association between TCIs and cancer among patients with atopic and endogenous eczema.

Methods: Incident cancers were identified from the National Cancer Registry. Data were analyzed using the Cox proportional hazards model to estimate hazard ratios (HRs) and 95% confidence intervals. Results: 880 unique cases of cancer developed in 66 176 patients from 2004 to 2012. The adjusted HRs for overall malignancy were 0.82 (95%CI 0.44–1.39) for tacrolimus-exposed and 1.30 (95%CI 0.59–2.45) for pimecrolimus-exposed. The only significant cancer association observed was lymphoid leukemia among the tacrolimus-exposed: HR 7.58 (95%CI 1.64–25.8). All affected patients had young-onset B-cell leukemia. Subgroup analysis of pediatric patients (≤16 years) showed significant association between tacrolimus use and B-cell leukemia: HR 26.4 (95%CI 4.77–146). Conclusions: In this first Asian study on the risk of TCIs and malignancies, we do not find an association between use of tacrolimus and pimecrolimus in atopic and endogenous eczema and the overall development of malignancies. However, the use of topical tacrolimus was found to be associated with the development of B-cell acute lymphoid leukemia in pediatric eczema patients; further studies are required to investigate if a true association indeed occurs.

Keywords:

• Tacrolimus
• malignancy
• atopic
• pimecrolimus
• adverse

Acknowledgements

We thank the assisting team from the National Registry of Diseases Office (NRDO), Singapore, for their invaluable help and support in providing the cancer data for this study, and enabling us to conduct the data analysis at the NRDO.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.